Does atorvastatin induce aortic smooth muscle cell apoptosis in vivo?

Vascular Pharmacology

Volumn 54, Issue 1-2, 2011, Pages 5-12

  Doyon, Marielle ^a   Hale, Taben Mary ^a,b   Huot Marchand, Julie Emilie ^a   Wu, Rong ^a   de Champlain, Jacques ^a   deBlois, Denis ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Amlodipine; Apoptosis; Atorvastatin; Combination therapy; Spontaneously hypertensive rat; Vascular remodeling

Indexed keywords

AMLODIPINE; ATORVASTATIN; DNA; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA MEDIA; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ESSENTIAL HYPERTENSION; HYPERPLASIA; IN VIVO STUDY; MALE; MUSCLE HYPERTROPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; SPONTANEOUSLY HYPERTENSIVE RAT;

AMLODIPINE; ANIMALS; AORTA; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OXIDATIVE STRESS; PYRROLES; RATS; RATS, INBRED SHR;

EID: 79952625581     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2010.10.001     Document Type: Article

References (71)

1. Abetel G., Poget P.N., Bonnabry J.P. Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin). A pilot study. Schweiz Med. Wochenschr. 1998, 128:272-277.
2. Auer J., Berent R., Weber T., Eber B. Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr. Med. Chem. 2002, 9:1831-1850.
3. Baetta R., Donetti E., Comparato C., Calore M., Rossi A., Teruzzi C., Paoletti R., Fumagalli R., Soma M.R. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol. Res. 1997, 36:115-121.
4. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J., Isaacsohn J.L., Weiss S.R., Keilson L.M., Brown W.V., Miller V.T., Shurzinske L.J., Black D.M. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Jama 1996, 275:128-133.
5. Bennett M.R., Evan G.I., Newby A.C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ. Res. 1994, 74:525-536.
6. Bennett M.R., Evan G.I., Schwartz S.M. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J. Clin. Invest. 1995, 95:2266-2274.
7. Blanco-Colio L.M., Villa A., Ortego M., Hernandez-Presa M.A., Pascual A., Plaza J.J., Egido J. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002, 161:17-26.
8. Borghi C., Dormi A., Veronesi M., Immordino V., Ambrosioni E. Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J. Clin. Hypertens. (Greenwich) 2002, 4:277-285.
9. Briones A.M., Rodriguez-Criado N., Hernanz R., Garcia-Redondo A.B., Rodrigues-Diez R.R., Alonso M.J., Egido J., Ruiz-Ortega M., Salaices M. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 2009, 54:142-149.
10. Campbell G.R., Campbell J.H. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp. Mol. Pathol. 1985, 42:139-162.
11. Chamley-Campbell J., Campbell G.R., Ross R. The smooth muscle cell in culture. Physiol. Rev. 1979, 59:1-61.
12. Chen H.J., Yao L., Chen T.G., Yu M., Wang L.H., Chen J.Z. Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats. Chin. Med. J. (Engl) 2007, 120:1902-1907.
13. Cohn J., Neutel J., Houston H. Early improvements in vascular compliance following coadministration of amlodipine and atorvastatin in patients with concomitant hypertension and dyslipidemia: the Avalon Arterial Wall Compliance (AWC) trial. Journal 2005.
14. deBlois D., Tea B.S., Than V.D., Tremblay J., Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 1997, 29:340-349.
15. deBlois D., Tea B.S., Beaudry D., Hamet P. Regulation of therapeutic apoptosis: a potential target in controlling hypertensive organ damage. Can. J. Physiol. Pharmacol. 2005, 83:29-41.
16. Delbosc S., Cristol J.P., Descomps B., Mimran A., Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002, 40:142-147.
17. Der Sarkissian S., Marchand E.L., Duguay D., Hamet P., deBlois D. Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril. Cardiovasc. Res. 2003, 57:775-783.
18. Duguay D., Der Sarkissian S., Kouz R., Ongali B., Couture R., deBlois D. Kinin B2 receptor is not involved in enalapril-induced apoptosis and regression of hypertrophy in spontaneously hypertensive rat aorta: possible role of B1 receptor. Br. J. Pharmacol. 2004, 141:728-736.
19. Duguay D., deBlois D. Differential regulation of Akt, caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine. Br. J. Pharmacol. 2007, 151:1315-1323.
20. Erl W., Hristov M., Neureuter M., Yan Z.Q., Hansson G.K., Weber P.C. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 2003, 169:251-258.
21. Erl W. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis?. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2005, 5:135-144.
22. Erl W. Atorvastatin-induced downregulation of survivin and vascular smooth muscle cell apoptosis: a causal relationship in restenosis?. Cardiovasc. Drugs Ther. 2007, 21:141-144.
23. Ferrier K.E., Muhlmann M.H., Baguet J.P., Cameron J.D., Jennings G.L., Dart A.M., Kingwell B.A. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J. Am. Coll. Cardiol. 2002, 39:1020-1025.
24. Ge C.J., Hu S.J., Wu Y.S., Chen N.Y. Effects of atorvastatin on vascular remodeling in spontaneously hypertensive rats. J. Zhejiang Univ. Sci. 2003, 4:612-615.
25. Gellman J., Ezekowitz M.D., Sarembock I.J., Azrin M.A., Nochomowitz L.E., Lerner E., Haudenschild C.C. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit. J. Am. Coll. Cardiol. 1991, 17:251-259.
26. Glorioso N., Troffa C., Filigheddu F., Dettori F., Soro A., Parpaglia P.P., Collatina S., Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281-1286.
27. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., Diaz C., Hernandez G., Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ. Res. 1998, 83:490-500.
28. Guijarro C., Blanco-Colio L.M., Massy Z.A., O'Donnell M.P., Kasiske B.L., Keane W.F., Egido J. Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int. Suppl. 1999, 71:S88-S91.
29. Hattori Y., Nakanishi N., Kasai K. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc. Res. 2002, 54:649-658.
30. Herdeg C., Fitzke M., Oberhoff M., Baumbach A., Schroeder S., Karsch K.R. Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits. Int. J. Cardiol. 2003, 91:59-69.
31. Holm A.M., Andersen C.B., Haunso S., Hansen P.R. ACE-inhibition promotes apoptosis after balloon injury of rat carotid arteries. Cardiovasc. Res. 2000, 45:777-782.
32. Ichiki T., Takeda K., Tokunou T., Iino N., Egashira K., Shimokawa H., Hirano K., Kanaide H., Takeshita A. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc. Biol. 2001, 21:1896-1901.
33. Ikeda U., Shimada K. Pleiotropic effects of statins on the vascular tissue. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2001, 1:51-58.
34. Indolfi C., Cioppa A., Stabile E., Di Lorenzo E., Esposito G., Pisani A., Leccia A., Cavuto L., Stingone A.M., Chieffo A., Capozzolo C., Chiariello M. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J. Am. Coll. Cardiol. 2000, 35:214-221.
35. Jiang J., Roman R.J. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997, 30:968-974.
36. Kaneider N.C., Reinisch C.M., Dunzendorfer S., Meierhofer C., Djanani A., Wiedermann C.J. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 2001, 158:23-33.
37. Knapp A.C., Huang J., Starling G., Kiener P.A. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis 2000, 152:217-227.
38. Kolyada A., Madias N. HMGCoA Reductase inhibitors induce apoptosis in rat aortic vascular smooth muscle cells. J. Am. Soc. Nephrol. 1996, 7:1433. Meeting abstract.
39. Krause B.R., Newton R.S. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1995, 117:237-244.
40. Laufs U., Liao J.K. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc. Med. 2000, 10:143-148.
41. Leibovitz E., Beniashvili M., Zimlichman R., Freiman A., Shargorodsky M., Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am. J. Hypertens. 2003, 16:715-718.
42. Lemay J., Tea B.S., Hamet P., deBlois D. Regression of neointimal lesions in the carotid artery of nifedipine-treated SHR and WKY rats: possible role of apoptosis. J. Vasc. Res. 2001, 38:462-470.
43. Levy B.I., Duriez M., Phillipe M., Poitevin P., Michel J.B. Effect of chronic dihydropyridine (isradipine) on the large arterial walls of spontaneously hypertensive rats. Circulation 1994, 90:3024-3033.
44. Marchand E.L., Der Sarkissian S., Hamet P., deBlois D. Caspase-dependent cell death mediates the early phase of aortic hypertrophy regression in losartan-treated spontaneously hypertensive rats. Circ. Res. 2003, 92:777-784.
45. Martinet W., Schrijvers D.M., Timmermans J.P., Bult H. Interactions between cell death induced by statins and 7-ketocholesterol in rabbit aorta smooth muscle cells. Br. J. Pharmacol. 2008, 154:1236-1246.
46. Mason R.P. Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine. Am. J. Cardiol. 2001, 88:2M-6M.
47. Mason R.P. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am. J. Med. 2005, 118 Suppl 12A:54-61.
48. Mason R.P., Walter M.F., Day C.A., Jacob R.F. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am. J. Cardiol. 2005, 96:11F-23F.
49. Mason R.P. Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management. Drugs 2008, 68:885-900.
50. Muller C., Kiehl M.G., van de Loo J., Koch O.M. Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Int. J. Mol. Med. 1999, 3:63-68.
51. Mulvany M.J. Vascular remodelling of resistance vessels: can we define this?. Cardiovasc. Res. 1999, 41:9-13.
52. Mulvany M.J. Small artery remodelling in hypertension: causes, consequences and therapeutic implications. Med. Biol. Eng. Comput. 2008, 46:461-467.
53. Munzel T., Sayegh H., Freeman B.A., Tarpey M.M., Harrison D.G. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J. Clin. Invest. 1995, 95:187-194.
54. Nawrocki J.W., Weiss S.R., Davidson M.H., Sprecher D.L., Schwartz S.L., Lupien P.J., Jones P.H., Haber H.E., Black D.M. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc. Biol. 1995, 15:678-682.
55. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 1993, 91:2546-2551.
56. Reddy R., Chahoud G., Mehta J.L. Modulation of cardiovascular remodeling with statins: fact or fiction?. Curr. Vasc. Pharmacol. 2005, 3:69-79.
57. Rodriguez-Vita J., Sanchez-Galan E., Santamaria B., Sanchez-Lopez E., Rodrigues-Diez R., Blanco-Colio L.M., Egido J., Ortiz A., Ruiz-Ortega M. Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation. PLoS One 2008, 3:e3959.
58. Sato M., Ohsaki Y., Tobise K. Transforming growth factor-beta 1 proliferated vascular smooth muscle cells from spontaneously hypertensive rats. Am. J. Hypertens. 1995, 8:160-166.
59. Schwartz S.M., deBlois D., O'Brien E.R. The intima. Soil for atherosclerosis and restenosis. Circ. Res. 1995, 77:445-465.
60. Sever P., Dahlof B., Poulter N., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S., Kristinsson A., McInnes G., Mehlsen J., Nieminem M., O'Brien E., Ostergren J. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur. Heart J. 2006, 27:2982-2988.
61. Sindermann J., Weigel K., Muller J., Breithardt G. Lovastatin causes down regulation of cyclin-dependent kinase-2, up-regulation of tyrosine phosphorylation and is capable of inducing apoptosis in human, bovine and rat vascular smooth-muscle cells. Circulation 1996, 94:3735. Meeting abstract.
62. Sindermann J.R., Fan L., Weigel K.A., Troyer D., Muller J.G., Schmidt A., March K.L., Breithardt G. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 2000, 150:331-341.
63. Soma M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., Paoletti R. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler. Thromb 1993, 13:571-578.
64. Takahashi M., Ogata Y., Okazaki H., Takeuchi K., Kobayashi E., Ikeda U., Shimada K. Fluvastatin enhances apoptosis in cytokine-stimulated vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 2002, 39:310-317.
65. Tea B.S., Dam T.V., Moreau P., Hamet P., deBlois D. Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension 1999, 34:229-235.
66. Teiger E., Than V.D., Richard L., Wisnewsky C., Tea B.S., Gaboury L., Tremblay J., Schwartz K., Hamet P. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J. Clin. Invest. 1996, 97:2891-2897.
67. Trion A., de Maat M., Jukema W., Maas A., Offerman E., Havekes L., Szalai A., van der Laarse A., Princen H., Emeis J. Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. J. Cardiovasc. Pharmacol. 2006, 47:89-95.
68. Wassmann S., Laufs U., Baumer A.T., Muller K., Ahlbory K., Linz W., Itter G., Rosen R., Bohm M., Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37:1450-1457.
69. Wolfrum S., Jensen K.S., Liao J.K. Endothelium-dependent effects of statins. Arterioscler. Thromb Vasc. Biol. 2003, 23:729-736.
70. Xu Y.G., Zhou S.H., Li Y.G., Zheng C.H., Li X.P., Liu Q.M., Xu D.M., Chen S. The mechanism underlying vascular smooth muscle cell apoptosis induced by atorvastatin may be mainly associated with down-regulation of survivin expression. Cardiovasc. Drugs Ther. 2007, 21:145-153.
71. Zhou M.S., Jaimes E.A., Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004, 44:186-190.